search
Back to results

Transforaminal Lumbar Interbody Fusion (TLIF) (TLIF)

Primary Purpose

Degenerative Disease of the Lumbosacral Spine

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Infuse™ Bone Graft (Infuse™)
Intervertebral body fusion device and Medtronic posterior Fixation Systems
Sponsored by
Medtronic Spinal and Biologics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Degenerative Disease of the Lumbosacral Spine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

A subject must meet all of the following inclusion criteria to participate in this study:

  • I.1. Has degenerative disease of the lumbosacral spine in one or two adjacent levels (L2 to S1) that results in radiculopathy secondary to nerve root compression, manifested by:

    1. History of radiating leg or buttock pain, paresthesia, numbness or weakness, or
    2. History of neurogenic claudication.
  • I.2. Has a history of low back pain.
  • I.3. Has radiographic evidence (e.g. CT, MRI, x-ray, etc.) of degenerative lumbosacral disease including at least one of the following:

    1. Instability up to and including Grade 2 spondylolisthesis/retrolisthesis based on the Meyerding classification (Meyerding, HW, 1932), or lateral listhesis demonstrated by coronal plane translation (slippage) of the superior (cranial) vertebral body lateral to the inferior (caudal) vertebral body less than or equal to 3mm, or
    2. Stenosis, or narrowing, of the lumbar spinal canal and/or intervertebral foramen requiring significant decompression leading to segmental instability, or
    3. Recurrent disc herniation
  • I.4. Has preoperative Oswestry Disability Index score ≥ 35.

Has to meet either inclusion criteria 5 or 6 to qualify for the study:

  • I.5. Has preoperative back and leg pain scores of (back pain ≥ 4 and leg pain ≥ 1) based on the Preoperative Back and Leg Pain Questionnaire.
  • I.6. Has preoperative back and leg pain scores of (back pain ≥ 1 and leg pain ≥ 4) based on the Preoperative Back and Leg Pain Questionnaire.
  • I.7. Is at least 18 years of age and skeletally mature at the time of surgery.
  • I.8. Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of six months.
  • I.9. Is willing and able to comply with the study plan and able to understand and sign the subject Informed Consent Form.

Exclusion Criteria:

A subject will be excluded from participating in this study for any of the following reasons:

  • E.1 Prior surgical procedure at the involved or adjacent spinal levels (e.g. bony decompression, fusion, arthroplasty, and/or other non-fusion procedures). Prior discectomy and/or laminectomy at the target or adjacent levels is allowed.
  • E.2 Significant lumbar instability defined as sagittal listhesis greater than Grade 2 at any involved level using the Meyerding Classification or lateral listhesis greater than 3 mm at any involved level.
  • E.3 Planned use of an internal or external bone growth stimulator.
  • E.4 Lumbar scoliosis >30 degrees.
  • E.5 Patients who had a previous diagnosis of osteoporosis with a T-score of -2.5 or below in the last 12 months existing together with a prevalent fragility fracture. (If subject has a prevalent fragility fracture and a T-score hasn't been assessed in the last 12 months, a DEXA will need to be obtained.)
  • E.6 Morbidly obese, as defined by a Body Mass Index (BMI) >40.
  • E.7 Presence of active malignancy or prior history of malignancy (non-invasive basal cell carcinoma of the skin and non-invasive squamous cell carcinoma localized only to the skin is allowed).
  • E.8 Overt or active bacterial infection, either local to surgical space or systemic.
  • E.9 Has undergone administration of any type of corticosteroid, anti-neoplastic, immunostimulating, or immunosuppressive agents, or medications known to inhibit with the healing of bone or soft tissue within 30 days prior to implantation of the assigned treatment

    • This includes patients ≥ 65 years of age taking warfarin with documented diagnosed osteoporosis. All other patients taking warfarin should washout for at least 5 days prior to treatment
    • Use of steroidal inhalers, short-term NSAID use, and short-term steroidal use (e.g. Medrol Dosepak) is allowed pre and postoperatively. For this clinical study, short-term use is defined as ≤ two weeks.
    • Use of NSAIDs and/or steroids for longer than two weeks postoperatively through the 24 Month Follow-Up Visit is prohibited.
  • E.10 Co-morbidities, which in the investigator's opinion, precludes the subject from being a surgical candidate.
  • E.11 Autoimmune disease, which in the investigator's opinion, is known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease, Hashimoto's thyroiditis).
  • E.12 Any endocrine or metabolic disorder, which in the investigator's opinion, is known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta).
  • E.13 Known exposure to any recombinant proteins used for bone formation (e.g., Infuse™ Bone Graft, OP-1 Putty, OP-1 Implant, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft).
  • E.14 Known hypersensitivity or allergy to any components of the study treatments including, but not limited to bone morphogenetic proteins (BMPs); injectable collagen; protein pharmaceuticals (e.g.,monoclonal antibodies or gamma globulins); bovine collagen products; and/or instrumentation materials (e.g., titanium, titanium alloy, cobalt chrome, cobalt chrome alloy, or PEEK).
  • E.15 History of any allergy resulting in anaphylaxis.
  • E.16 Is a prisoner.
  • E.17 Is mentally incompetent. If questionable, obtain psychiatric consult.
  • E.18 Treatment with an investigational therapy (drug, device, and/or biologic) targeting spinal conditions within 3 months prior to implantation surgery, treatment with any other investigational therapies within 30 days prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment.
  • E.19 Pregnant or nursing. Females of child-bearing potential must agree not to become pregnant for 24 months following surgery.
  • E.20 A documented diagnosis of substance use disorder as defined by the DSM-5.22 (Nicotine use is allowed.)
  • E.21 Pursuing worker's compensation or active litigation for spinal fusion procedure.
  • E.22 Any condition, which in the investigator's opinion, would interfere with the subject's ability to comply with study instructions, which might confound data interpretation.

Sites / Locations

  • Mayo ClinicRecruiting
  • University of California IrvineRecruiting
  • Memorial Health ServicesRecruiting
  • Cedars Sinai Spine CenterRecruiting
  • University of California Davis Medical CenterRecruiting
  • Boulder Neurosurgical Associates and Justin Parker Neurological Institute/E. Lee NelsonRecruiting
  • Vail-Summit Orthopaedics and NeurosurgeryRecruiting
  • Orlando HealthRecruiting
  • Northwestern MedicineRecruiting
  • Rush University Medical CenterRecruiting
  • Goodman Campbell Brain and SpineRecruiting
  • Indiana Spine GroupRecruiting
  • OrthoIndy Northwest Office
  • University of Kansas Medical Center Research Institute
  • Lahey Hospital & Medical CenterRecruiting
  • Baystate Medical Center
  • University of Michigan Health SystemRecruiting
  • William Beaumont Hospital
  • Mayo ClinicRecruiting
  • Montefiore Medical CenterRecruiting
  • NYU Langone Health
  • Hospital for Special SurgeryRecruiting
  • Icahn School of Medicine at Mount SinaiRecruiting
  • University of North CarolinaRecruiting
  • Mayfield Brain and Spine ClinicRecruiting
  • The Ohio State University Wexner Medical CenterRecruiting
  • Penn State-HersheyRecruiting
  • Rothman InstituteRecruiting
  • Semmes Murphey
  • Saint Thomas for Specialty SurgeryRecruiting
  • Tennessee Orthopaedic AllianceRecruiting
  • Ascension Texas Spine and Scoliosis
  • DFW Center for Spinal DisorderRecruiting
  • Houston Methodist HospitalRecruiting
  • American Neurospine InstituteRecruiting
  • University of Virginia - Clinical Trial OfficeRecruiting
  • University of Virginia - Health SystemRecruiting
  • Swedish NeuroscienceRecruiting
  • West Virginia University, 1 Medical Center DriveRecruiting
  • Medical College of WisconsinRecruiting
  • Peking University Third HospitalRecruiting
  • West China Hospital of Sichuan UniversityRecruiting
  • Chongqing Xinqiao Hospital Second Affiliated Hospital of Army Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Group #1

Group #2

Control

Arm Description

Investigational Infuse™ 2.1 mg/level with available local bone autograft and supplemented with cancellous allograft as needed

Investigational Infuse™ 4.2 mg/level with available local bone autograft and supplemented with cancellous allograft as needed

Local bone autograft and supplemented with cancellous allograft as needed.

Outcomes

Primary Outcome Measures

Overall success at 24 months
Overall success is defined as the participant who meet the following five criteria: Pain/disability (ODI) success, defined as at least a 15-point improvement from baseline; Fusion success as defined in primary outcome 2. Neurological success, defined as maintenance or improvement in neurological status; No SAE related to the TLIF grafting material or interbody device; and No secondary surgeries at index level that are related to the TLIF grafting material or interbody device
Fusion success at 24 months
Fusion success at each treatment level must demonstrate: Evidence of bridging bone via CT. Solid fusion is based on evidence of continuous bone bridging from the superior to the inferior vertebral body at the target level(s) in at least 1 of the following locations: right lateral, left lateral, anterior, posterior, or through the PEEK implant. No evidence of motion as defined by less than 3mm translational motion and less than 5o in angular motion at each treated level

Secondary Outcome Measures

Time to fusion
The first time point when a subject's fusion status has been determined to be a success per the fusion success criteria
ODI success
The self-administered Oswestry Disability Index (ODI) will be used. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). Success will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score ≥ 15 points
Leg pain success
Numerical rating scales (NRS 0-10) will be used to measure leg pain, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be. Success for leg pain is defined as at least 20% improvement from pre-operative score: (Preoperative Score - Postoperative Score) / Preoperative Score ≥ 20%
Back pain success
Numerical rating scales (NRS 0-10) will be used to measure back pain, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be". Success for back pain is defined as at least 20% improvement from pre-operative score: (Preoperative Score - Postoperative Score) / Preoperative Score ≥ 20%
Neurological success
Overall neurological success is defined as maintenance or improvement in four key neurological assessments: motor function, sensory function, reflexes, and straight leg raise. In order to be considered a success, each element in the motor, sensory, reflexes, and straight leg raise examinations must remain the same or improve from the time of the preoperative evaluation to the time period evaluated. Therefore, if any one motor, sensory, or reflexes element does not stay the same or improve, then a subject will not be considered a success for neurological status.
Serious Adverse Events
Serious Adverse Events related to TLIF grafting material or interbody device up to 24 months
Secondary Surgery
Secondary surgeries that are classified as a "failure", defined as any secondary surgeries at index level(s) "related" to TLIF grafting material or interbody device.

Full Information

First Posted
August 27, 2019
Last Updated
October 20, 2023
Sponsor
Medtronic Spinal and Biologics
search

1. Study Identification

Unique Protocol Identification Number
NCT04073563
Brief Title
Transforaminal Lumbar Interbody Fusion (TLIF)
Acronym
TLIF
Official Title
Prospective, Randomized, Controlled, Blinded Pivotal Study In Subjects Undergoing A Transforaminal Lumbar Interbody Fusion (TLIF) At One Or Two Levels Using Infuse™ Bone Graft With an Intervertebral Body Fusion Device and Posterior Supplemental Fixation For The Treatment Of Symptomatic Degenerative Disease Of The Lumbosacral Spine
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 19, 2019 (Actual)
Primary Completion Date
April 2026 (Anticipated)
Study Completion Date
April 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Spinal and Biologics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 1017 subjects will be enrolled and treated. The purpose of the study is to provide safety and effectiveness data of Infuse™ in A Transforaminal Lumbar Interbody Fusion (TLIF) procedures and to obtain indication expansion for Infuse™ use in one and two level TLIF procedures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disease of the Lumbosacral Spine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
1017 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group #1
Arm Type
Experimental
Arm Description
Investigational Infuse™ 2.1 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
Arm Title
Group #2
Arm Type
Experimental
Arm Description
Investigational Infuse™ 4.2 mg/level with available local bone autograft and supplemented with cancellous allograft as needed
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Local bone autograft and supplemented with cancellous allograft as needed.
Intervention Type
Device
Intervention Name(s)
Infuse™ Bone Graft (Infuse™)
Intervention Description
(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
Intervention Type
Device
Intervention Name(s)
Intervertebral body fusion device and Medtronic posterior Fixation Systems
Intervention Description
Adaptix™Interbody System, Capstone™ Spinal System, Catalyft™ PL Interbody System
Primary Outcome Measure Information:
Title
Overall success at 24 months
Description
Overall success is defined as the participant who meet the following five criteria: Pain/disability (ODI) success, defined as at least a 15-point improvement from baseline; Fusion success as defined in primary outcome 2. Neurological success, defined as maintenance or improvement in neurological status; No SAE related to the TLIF grafting material or interbody device; and No secondary surgeries at index level that are related to the TLIF grafting material or interbody device
Time Frame
24 months
Title
Fusion success at 24 months
Description
Fusion success at each treatment level must demonstrate: Evidence of bridging bone via CT. Solid fusion is based on evidence of continuous bone bridging from the superior to the inferior vertebral body at the target level(s) in at least 1 of the following locations: right lateral, left lateral, anterior, posterior, or through the PEEK implant. No evidence of motion as defined by less than 3mm translational motion and less than 5o in angular motion at each treated level
Time Frame
24 Months
Secondary Outcome Measure Information:
Title
Time to fusion
Description
The first time point when a subject's fusion status has been determined to be a success per the fusion success criteria
Time Frame
From surgery to 24 Months
Title
ODI success
Description
The self-administered Oswestry Disability Index (ODI) will be used. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). Success will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score ≥ 15 points
Time Frame
24 months
Title
Leg pain success
Description
Numerical rating scales (NRS 0-10) will be used to measure leg pain, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be. Success for leg pain is defined as at least 20% improvement from pre-operative score: (Preoperative Score - Postoperative Score) / Preoperative Score ≥ 20%
Time Frame
24 months
Title
Back pain success
Description
Numerical rating scales (NRS 0-10) will be used to measure back pain, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be". Success for back pain is defined as at least 20% improvement from pre-operative score: (Preoperative Score - Postoperative Score) / Preoperative Score ≥ 20%
Time Frame
24 months
Title
Neurological success
Description
Overall neurological success is defined as maintenance or improvement in four key neurological assessments: motor function, sensory function, reflexes, and straight leg raise. In order to be considered a success, each element in the motor, sensory, reflexes, and straight leg raise examinations must remain the same or improve from the time of the preoperative evaluation to the time period evaluated. Therefore, if any one motor, sensory, or reflexes element does not stay the same or improve, then a subject will not be considered a success for neurological status.
Time Frame
24 months
Title
Serious Adverse Events
Description
Serious Adverse Events related to TLIF grafting material or interbody device up to 24 months
Time Frame
up to 24 months
Title
Secondary Surgery
Description
Secondary surgeries that are classified as a "failure", defined as any secondary surgeries at index level(s) "related" to TLIF grafting material or interbody device.
Time Frame
up to 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A subject must meet all of the following inclusion criteria to participate in this study: I.1. Has degenerative disease of the lumbosacral spine in one or two adjacent levels (L2 to S1) that results in radiculopathy secondary to nerve root compression, manifested by: History of radiating leg or buttock pain, paresthesia, numbness or weakness, or History of neurogenic claudication. I.2. Has a history of low back pain. I.3. Has radiographic evidence (e.g. CT, MRI, x-ray, etc.) of degenerative lumbosacral disease including at least one of the following: Instability up to and including Grade 2 spondylolisthesis/retrolisthesis based on the Meyerding classification (Meyerding, HW, 1932), or lateral listhesis demonstrated by coronal plane translation (slippage) of the superior (cranial) vertebral body lateral to the inferior (caudal) vertebral body less than or equal to 3mm, or Stenosis, or narrowing, of the lumbar spinal canal and/or intervertebral foramen requiring significant decompression leading to segmental instability, or Recurrent disc herniation I.4. Has preoperative Oswestry Disability Index score ≥ 35. Has to meet either inclusion criteria 5 or 6 to qualify for the study: I.5. Has preoperative back and leg pain scores of (back pain ≥ 4 and leg pain ≥ 1) based on the Preoperative Back and Leg Pain Questionnaire. I.6. Has preoperative back and leg pain scores of (back pain ≥ 1 and leg pain ≥ 4) based on the Preoperative Back and Leg Pain Questionnaire. I.7. Is at least 18 years of age and skeletally mature at the time of surgery. I.8. Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of six months. I.9. Is willing and able to comply with the study plan and able to understand and sign the subject Informed Consent Form. Exclusion Criteria: A subject will be excluded from participating in this study for any of the following reasons: E.1 Prior surgical procedure at the involved or adjacent spinal levels (e.g. fusion, arthroplasty, and/or other non-fusion procedures). Prior discectomy and/or laminectomy at the target or adjacent levels is allowed. E.2 Significant lumbar instability defined as sagittal listhesis greater than Grade 2 at any involved level using the Meyerding Classification or lateral listhesis greater than 3 mm at any involved level. E.3 Planned use of an internal or external bone growth stimulator. E.4 Lumbar scoliosis >30 degrees. E.5 Patients who had a previous diagnosis of osteoporosis with a T-score of -2.5 or below in the last 12 months existing together with a prevalent fragility fracture. (If subject has a prevalent fragility fracture and a T-score hasn't been assessed in the last 12 months, a DEXA will need to be obtained.) E.6 Morbidly obese, as defined by a Body Mass Index (BMI) >40. E.7 Presence of active malignancy or prior history of malignancy (non-invasive basal cell carcinoma of the skin and non-invasive squamous cell carcinoma localized only to the skin is allowed). E.8 Overt or active bacterial infection, either local to surgical space or systemic. E.9 Has undergone administration of any type of corticosteroid, antineoplastic, immunostimulating, or immunosuppressive agents, or medications known to inhibit the healing of bone or soft tissue within 30 days prior to implantation of the assigned treatment. This includes patients ≥ 65 years of age taking warfarin with documented diagnosed osteoporosis. All other patients taking warfarin should washout for at least 5 days prior to treatment Use of steroidal inhalers is allowed pre- and post-operatively Short-term steroidal use (e.g., Medrol Dosepak) is allowed pre and post-operatively. For this clinical study, short-term use is defined as ≤ two weeks. Use of steroids for longer than two weeks post-operatively through the 24-month follow-up visit is prohibited. E.10 Co-morbidities, which in the investigator's opinion, precludes the subject from being a surgical candidate. E.11 Autoimmune disease, which in the investigator's opinion, is known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease, Hashimoto's thyroiditis). E.12 Any endocrine or metabolic disorder, which in the investigator's opinion, is known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta). E.13 Known exposure to any recombinant proteins used for bone formation (e.g., Infuse™ Bone Graft, OP-1 Putty, OP-1 Implant, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft). E.14 Known hypersensitivity or allergy to any components of the study treatments including, but not limited to bone morphogenetic proteins (BMPs); injectable collagen; protein pharmaceuticals (e.g.,monoclonal antibodies or gamma globulins); bovine collagen products; and/or instrumentation materials (e.g., titanium, titanium alloy, cobalt chrome, cobalt chrome alloy, or PEEK). E.15 History of any allergy resulting in anaphylaxis. E.16 Is a prisoner. E.17 Is mentally incompetent. If questionable, obtain psychiatric consult. E.18 Treatment with an investigational therapy (drug, device, and/or biologic) targeting spinal conditions within 3 months prior to implantation surgery, treatment with any other investigational therapies within 30 days prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment. E.19 Pregnant or nursing. Females of child-bearing potential must agree not to become pregnant for 24 months following surgery. E.20 A documented diagnosis of substance use disorder as defined by the DSM-5.22 (Nicotine use is allowed.) E.21 Pursuing worker's compensation or active litigation for spinal fusion procedure. E.22 Any condition, which in the investigator's opinion, would interfere with the subject's ability to comply with study instructions, which might confound data interpretation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lindsey Mitchell, MS
Phone
763-505-0264
Email
Lindsey.Mitchell@medtronic.com
Facility Information:
Facility Name
Mayo Clinic
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haydee Salgado Broncano
Email
salgadobroncano.haydee@mayo.edu
First Name & Middle Initial & Last Name & Degree
Jamal McClendon
First Name & Middle Initial & Last Name & Degree
Chandan Krishna
Facility Name
University of California Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92617
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brandon Lehman
Email
bdlehman@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Michael Oh
First Name & Middle Initial & Last Name & Degree
Kiarash Golshani
First Name & Middle Initial & Last Name & Degree
Frank Hsu
Facility Name
Memorial Health Services
City
Laguna Hills
State/Province
California
ZIP/Postal Code
92653
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darin Johnson
Email
djpaocna@gmail.com
First Name & Middle Initial & Last Name & Degree
Robert Jackson
Facility Name
Cedars Sinai Spine Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Linda Kanim
Phone
310-248-1312
Email
linda.kanim@cshs.org
First Name & Middle Initial & Last Name & Degree
Hyun Bae
Facility Name
University of California Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janice Wang-Polagruto
Email
janice.wang-polagruto@ucdmc.ucdavis.edu
First Name & Middle Initial & Last Name & Degree
Kee Kim
Facility Name
Boulder Neurosurgical Associates and Justin Parker Neurological Institute/E. Lee Nelson
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80303
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sigita Burneikiene
Phone
303-938-5700
Email
Sigitab@bnasurg.com
First Name & Middle Initial & Last Name & Degree
Alan Villavicencio, MD
First Name & Middle Initial & Last Name & Degree
Sharad Rajpal, MD
First Name & Middle Initial & Last Name & Degree
Ewell Nelson, MD
Facility Name
Vail-Summit Orthopaedics and Neurosurgery
City
Vail
State/Province
Colorado
ZIP/Postal Code
81657
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jared Heinze
Email
jheinze@vsortho.com
First Name & Middle Initial & Last Name & Degree
Ernest Braxton
Facility Name
Orlando Health
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charlene S Carlo
Phone
321-841-1324
Email
charlene.carlo@orlandohealth.com
First Name & Middle Initial & Last Name & Degree
Virgilio Matheus, MD
First Name & Middle Initial & Last Name & Degree
Robert A Hirschl, MD
First Name & Middle Initial & Last Name & Degree
Marshall C Cress, MD
First Name & Middle Initial & Last Name & Degree
Paul M Foreman, MD
Facility Name
Northwestern Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saadia Sial
Email
saadia.sial@nm.org
First Name & Middle Initial & Last Name & Degree
Wellington Hsu, MD
First Name & Middle Initial & Last Name & Degree
Alpesh Patel, MD
First Name & Middle Initial & Last Name & Degree
Srikanth Divi, MD
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Porcha Davis
Email
porcha_d_davis@rush.edu
First Name & Middle Initial & Last Name & Degree
Harel Deutsch
Facility Name
Goodman Campbell Brain and Spine
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicole Lemrick
Email
nlemrick@goodmancampbell.com
First Name & Middle Initial & Last Name & Degree
Saad Khairi
First Name & Middle Initial & Last Name & Degree
Shannon McCanna
First Name & Middle Initial & Last Name & Degree
Eric Potts
First Name & Middle Initial & Last Name & Degree
Richard Rodgers
First Name & Middle Initial & Last Name & Degree
John DePowell
First Name & Middle Initial & Last Name & Degree
Charles Kulwin
First Name & Middle Initial & Last Name & Degree
Eric Horn
Facility Name
Indiana Spine Group
City
Carmel
State/Province
Indiana
ZIP/Postal Code
46032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sheetal Vinayek, M.Sc.
Phone
317-715-5897
Email
svinayek@indianaspinegroup.com
First Name & Middle Initial & Last Name & Degree
Joseph Smucker, MD
Facility Name
OrthoIndy Northwest Office
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46278
Country
United States
Individual Site Status
Terminated
Facility Name
University of Kansas Medical Center Research Institute
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Lahey Hospital & Medical Center
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Christopher
Email
susan.r.christopher@lahey.org
First Name & Middle Initial & Last Name & Degree
Zoher Ghogawala, MD
Facility Name
Baystate Medical Center
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01199
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Bell
Email
jennbell@med.umich.edu
First Name & Middle Initial & Last Name & Degree
Yamaan Saadeh
First Name & Middle Initial & Last Name & Degree
Osama Kashlan
Facility Name
William Beaumont Hospital
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55901
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cassandra Wilson
Phone
507-266-1227
Email
Kingsbury.Cassandra@mayo.edu
First Name & Middle Initial & Last Name & Degree
Brett Freedman
First Name & Middle Initial & Last Name & Degree
Benjamin Elder
First Name & Middle Initial & Last Name & Degree
Jeremy Fogelson
First Name & Middle Initial & Last Name & Degree
Arjun Sebastian
First Name & Middle Initial & Last Name & Degree
Mohamed Bydon
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Genesis Liriano
Email
gliriano@montefiore.org
First Name & Middle Initial & Last Name & Degree
Reza Yassari
First Name & Middle Initial & Last Name & Degree
Yaroslav Gelfand
Facility Name
NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Individual Site Status
Withdrawn
Facility Name
Hospital for Special Surgery
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fedan Avrumova
Email
avrumovaf@hss.edu
First Name & Middle Initial & Last Name & Degree
Darren Lebl
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ula Isleem
Email
ula.isleem@mountsinai.org
First Name & Middle Initial & Last Name & Degree
Samuel Cho
First Name & Middle Initial & Last Name & Degree
Jun Kim
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Wilson
Email
wilsons@neurology.unc.edu
First Name & Middle Initial & Last Name & Degree
Cheerag Upadhyaya
Facility Name
Mayfield Brain and Spine Clinic
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45209
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren Murphey
Email
lmurphy@mayfieldclinic.com
First Name & Middle Initial & Last Name & Degree
Robert Bohinski
Facility Name
The Ohio State University Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aladdin Alqaisi
Email
aladdin.alqaisi@osumc.edu
First Name & Middle Initial & Last Name & Degree
Stephanus Viljoen, MD
First Name & Middle Initial & Last Name & Degree
Andrew Grossbach, MD
First Name & Middle Initial & Last Name & Degree
David Xu
Facility Name
Penn State-Hershey
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivia Christman
Email
ochristman@pennstatehealth.psu.edu
First Name & Middle Initial & Last Name & Degree
George Reiter, MD
First Name & Middle Initial & Last Name & Degree
Michael Sather, MD
First Name & Middle Initial & Last Name & Degree
JP Kelleher, MD
Facility Name
Rothman Institute
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yen Sy
Email
yen.sy@rothmanortho.com
First Name & Middle Initial & Last Name & Degree
Gregory Schroeder
First Name & Middle Initial & Last Name & Degree
Victor Hsu
Facility Name
Semmes Murphey
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Courtney Berryman
Email
cberryman@semmes-murphey.com
First Name & Middle Initial & Last Name & Degree
Sonia Eden, MD
First Name & Middle Initial & Last Name & Degree
Paul Park, MD
Facility Name
Saint Thomas for Specialty Surgery
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lea Fuller
Email
lea.fuller@ascension.org
First Name & Middle Initial & Last Name & Degree
Jason Hubbard
Facility Name
Tennessee Orthopaedic Alliance
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37209
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Erika Fraizer
Email
frazieree@toa.com
First Name & Middle Initial & Last Name & Degree
Ryan Snowden
Facility Name
Ascension Texas Spine and Scoliosis
City
Austin
State/Province
Texas
ZIP/Postal Code
78731
Country
United States
Individual Site Status
Withdrawn
Facility Name
DFW Center for Spinal Disorder
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76132
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robin Keswani
Email
robin@researchtex.com
First Name & Middle Initial & Last Name & Degree
Jason Tinley
Facility Name
Houston Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haley Goble
Email
hmgoble@houstonmethodist.org
First Name & Middle Initial & Last Name & Degree
Comron Saifi
Facility Name
American Neurospine Institute
City
Plano
State/Province
Texas
ZIP/Postal Code
75075
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ezioma Akwara
Email
ezioma.akwara@hcahealthcare.com
First Name & Middle Initial & Last Name & Degree
Ripul Panchal
Facility Name
University of Virginia - Clinical Trial Office
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Judy Beenhakker
Phone
434-982-1856
Email
judybeen@virginia.edu
First Name & Middle Initial & Last Name & Degree
Mark Shaffrey
Facility Name
University of Virginia - Health System
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Milos Lesevic
Email
ml4ec@hscmail.mcc.virginia.edu
First Name & Middle Initial & Last Name & Degree
Adam Shimer
First Name & Middle Initial & Last Name & Degree
Francis Shen
First Name & Middle Initial & Last Name & Degree
Anuj Singla
Facility Name
Swedish Neuroscience
City
Seattle
State/Province
Washington
ZIP/Postal Code
98122
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yolanda Seegmiller
Email
yolonda.seegmiller@swedish.org
First Name & Middle Initial & Last Name & Degree
Jens Chapman
First Name & Middle Initial & Last Name & Degree
Rod Oskouian
Facility Name
West Virginia University, 1 Medical Center Drive
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Eicher
Email
jeicher@hsc.wvu.edu
First Name & Middle Initial & Last Name & Degree
John France, MD
First Name & Middle Initial & Last Name & Degree
Cara Sedney, MD
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Cornell
Email
scornell@mcw.edu
First Name & Middle Initial & Last Name & Degree
Saman Shabani
First Name & Middle Initial & Last Name & Degree
Brandon Rebholz
First Name & Middle Initial & Last Name & Degree
Aditya Vedantam
Facility Name
Peking University Third Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yilan Tian
Email
tian_yilan@wuxiapptec.com
First Name & Middle Initial & Last Name & Degree
Weishi Li
First Name & Middle Initial & Last Name & Degree
Shuai Jiang
First Name & Middle Initial & Last Name & Degree
Da Zou
First Name & Middle Initial & Last Name & Degree
Shengfa Pan
First Name & Middle Initial & Last Name & Degree
Xin Chen
First Name & Middle Initial & Last Name & Degree
Feifei Zhou
First Name & Middle Initial & Last Name & Degree
Li Zhang
First Name & Middle Initial & Last Name & Degree
Woquan Zhong
First Name & Middle Initial & Last Name & Degree
Xinhu Guo
First Name & Middle Initial & Last Name & Degree
Liang Jiang
First Name & Middle Initial & Last Name & Degree
Fengshan Zhang
First Name & Middle Initial & Last Name & Degree
Zhuoran Sun
First Name & Middle Initial & Last Name & Degree
Chuiguo Sun
First Name & Middle Initial & Last Name & Degree
Qiang Qi
First Name & Middle Initial & Last Name & Degree
Yan Zeng
First Name & Middle Initial & Last Name & Degree
Zhaoqing Guo
Facility Name
West China Hospital of Sichuan University
City
Chengdu
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liping Xiao
Phone
+86 15308315280
First Name & Middle Initial & Last Name & Degree
Yueming Song
First Name & Middle Initial & Last Name & Degree
Chunguang Zhou
First Name & Middle Initial & Last Name & Degree
Liang Wang
First Name & Middle Initial & Last Name & Degree
Quan Gong
First Name & Middle Initial & Last Name & Degree
Hua Chen
First Name & Middle Initial & Last Name & Degree
Ganjun Feng
First Name & Middle Initial & Last Name & Degree
Tao Li
First Name & Middle Initial & Last Name & Degree
Lei Wang
First Name & Middle Initial & Last Name & Degree
Peng Xiu
First Name & Middle Initial & Last Name & Degree
Limin Liu
First Name & Middle Initial & Last Name & Degree
Bangsheng Jia
First Name & Middle Initial & Last Name & Degree
Yuxiao Deng
First Name & Middle Initial & Last Name & Degree
Xi Yang
First Name & Middle Initial & Last Name & Degree
Zhongjie Zhou
Facility Name
Chongqing Xinqiao Hospital Second Affiliated Hospital of Army Medical University
City
Chongqing
ZIP/Postal Code
400000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chunyan Dai Dai
Email
dai_chunyan@wuxiapptec.com 
First Name & Middle Initial & Last Name & Degree
Changqing Li
First Name & Middle Initial & Last Name & Degree
He Zhang
First Name & Middle Initial & Last Name & Degree
Rui Zuo
First Name & Middle Initial & Last Name & Degree
Zhilei Hu
First Name & Middle Initial & Last Name & Degree
Minghan Liu
First Name & Middle Initial & Last Name & Degree
Chao Liu
First Name & Middle Initial & Last Name & Degree
Xian Chang
First Name & Middle Initial & Last Name & Degree
Huan Liu
First Name & Middle Initial & Last Name & Degree
Jian Wang
First Name & Middle Initial & Last Name & Degree
Wenjie Zheng
First Name & Middle Initial & Last Name & Degree
Chao Zhang
First Name & Middle Initial & Last Name & Degree
Yue Zhou
First Name & Middle Initial & Last Name & Degree
Yu Tang

12. IPD Sharing Statement

Learn more about this trial

Transforaminal Lumbar Interbody Fusion (TLIF)

We'll reach out to this number within 24 hrs